Regeneron And Teva's Fasinumab Crosses One Threshold; More Remain
Executive Summary
The companies reported positive Phase III data testing the nerve growth factor inhibitor in patients with chronic pain, but the efficacy appears modest and safety will remain a question until long-term Phase III data read out. The companies are focused on a lower 1 mg dose.